California State Teachers Retirement System Boosts Stock Holdings in Evelo Biosciences, Inc. (NASDAQ:EVLO)

California State Teachers Retirement System lifted its stake in shares of Evelo Biosciences, Inc. (NASDAQ:EVLO) by 20.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 41,923 shares of the company’s stock after acquiring an additional 7,188 shares during the quarter. California State Teachers Retirement System owned 0.08% of Evelo Biosciences worth $576,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Meeder Asset Management Inc. increased its position in shares of Evelo Biosciences by 87.3% during the second quarter. Meeder Asset Management Inc. now owns 4,856 shares of the company’s stock worth $67,000 after acquiring an additional 2,264 shares during the period. Alliancebernstein L.P. increased its position in shares of Evelo Biosciences by 25.2% during the second quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock worth $191,000 after acquiring an additional 2,800 shares during the period. Goldman Sachs Group Inc. increased its holdings in Evelo Biosciences by 25.3% in the first quarter. Goldman Sachs Group Inc. now owns 14,063 shares of the company’s stock valued at $150,000 after buying an additional 2,844 shares during the last quarter. Rhumbline Advisers increased its holdings in Evelo Biosciences by 15.4% in the second quarter. Rhumbline Advisers now owns 22,618 shares of the company’s stock valued at $311,000 after buying an additional 3,015 shares during the last quarter. Finally, Deutsche Bank AG increased its holdings in Evelo Biosciences by 21.0% in the second quarter. Deutsche Bank AG now owns 20,325 shares of the company’s stock valued at $280,000 after buying an additional 3,524 shares during the last quarter. 85.70% of the stock is currently owned by institutional investors and hedge funds.

Several equities analysts recently commented on the company. Chardan Capital raised Evelo Biosciences from a “neutral” rating to a “buy” rating and set a $12.00 target price on the stock in a report on Monday, November 1st. They noted that the move was a valuation call. Zacks Investment Research raised Evelo Biosciences from a “sell” rating to a “hold” rating in a report on Monday, November 15th. Jefferies Financial Group dropped their target price on Evelo Biosciences from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, September 28th. JMP Securities dropped their target price on Evelo Biosciences from $44.00 to $41.50 and set a “market outperform” rating on the stock in a report on Tuesday, November 2nd. Finally, BMO Capital Markets reissued a “buy” rating and issued a $23.00 target price on shares of Evelo Biosciences in a report on Sunday, October 31st. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $20.00.

NASDAQ EVLO opened at $8.51 on Monday. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.72 and a quick ratio of 4.72. Evelo Biosciences, Inc. has a 1 year low of $4.87 and a 1 year high of $19.93. The company has a market capitalization of $454.94 million, a PE ratio of -3.56 and a beta of 1.56. The company has a fifty day moving average of $8.60 and a two-hundred day moving average of $10.63.

Evelo Biosciences (NASDAQ:EVLO) last released its quarterly earnings data on Wednesday, October 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.09). During the same quarter in the prior year, the business posted ($0.45) EPS. On average, research analysts expect that Evelo Biosciences, Inc. will post -2.39 earnings per share for the current year.

Evelo Biosciences Profile

Evelo Biosciences, Inc operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases; EDP2939 for inflammation; and EDP1908 for oncology. The company was founded by Noubar B.

Featured Story: Understanding the Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Evelo Biosciences (NASDAQ:EVLO)